MiRNA210通过NUPR1基因靶向调控喉癌多药耐药性的研究  

The study of miRNA210 regulation in Multidrug resistance of laryngeal cancer through targeted NUPR1 gene

作　　者：何丹[1] 王苹[1] 李亚纯 尹万忠[1] HE Dan;WANG Ping;LI Ya-chun(Dept. of Otorhinolaryngology , Head and Neck Surgery , The First of Hospital,Jinlin University,Changchun 130021 ,China)

机构地区：[1]吉林大学第一医院耳鼻咽喉头颈外科,吉林长春130021

出　　处：《中国实验诊断学》2019年第3期511-515,共5页Chinese Journal of Laboratory Diagnosis

基　　金：吉林省教育厅课题(2016479);吉林省卫生厅课题(2018J071);吉林省发展改革委课题(2019C049-8)

摘　　要：目的研究miRNA210在喉癌多药耐药中的调控机制。方法采用荧光素酶报告基因载体实验验证并确定了miRNA210的靶基因,进而构建miRNA210抑制物载体,通过抑制miRNA210的表达,观察其对喉癌多药耐药的调控作用。结果 miRNA210靶基因为NUPR1,抑制miRNA210的表达,可明显增加喉癌细胞对化疗的敏感性,miRNA210可通过调控其靶基因的表达影响喉癌的多药耐药性。结论 miRNA210表达参与喉癌多药耐药的调控机制,以miRNA210为靶点的药物开发及逆转治疗有潜在应用前景。Objective To study the regulation mechanism of miRNA-210 in multidrug resistance of laryngeal cancer.Methods luciferase reporter gene vector test were used to identify the target genes of miRNA-210.Next,in order to observe the regulation effects of miRNA-210 on multidrug resistance(MDR)in laryngeal cancer,the miRNA-210 inhibitor vector was constructed to inhibit the expression of miRNA-210.Results Target gene of the miRNA-210 is NUPR1.It can significantly increase the sensitivity of laryngeal cancer cells to chemotherapy by inhibition of miRNA-210 expression.MiRNA210 can affect the multidrug resistance of laryngeal carcinoma by regulating the expression of its target genes.Conclusion The expression and regulatory of miRNA210 involved in MDR mechanism of in laryngeal carcinoma.Drug development and reversal therapy with targeting miRNA210 have potential application prospects.

关 键 词：喉癌 多药耐药 miRNA210 

分 类 号：R739.65[医药卫生—肿瘤]